IP Library › Granted Patent US 10,633,434
Granted Patent B2
US 10,633,434 · App. 15/621,689 · Granted Apr 28, 2020

Anti-C5 antibodies

Inventors: Ying Hu (Scarsdale, NY); Adrianna Latuszek (Sleepy Hollow, NY); Carmelo Romano (Tarrytown, NY); William Olson (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C07K16/18A61K39/3955A61K45/06A61K2039/505A61K2039/54C07K2317/21C07K2317/33C07K2317/34C07K2317/51C07K2317/515C07K2317/565C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,633,434
App. No.
15/621,689
Granted
Apr 28, 2020
Kind
B2
Abstract

The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.

Claims (18)

1. An antibody or antigen-binding fragment thereof that binds specifically to C5 comprising HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 comprising amino acid sequences of SEQ ID NOs: 100-102-104-108-110-112.

2. An antibody or antigen-binding fragment thereof that binds specifically to C5, wherein the antibody or antigen-binding fragment thereof comprises a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 98/106.

3. The antibody or antigen-binding fragment thereof of claim 2 comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 353.

4. The antibody or antigen-binding fragment thereof of claim 2 comprising a heavy chain and a light chain, wherein the light chain comprises an amino acid sequence of SEQ ID NO: 354.

5. An antibody or antigen-binding fragment thereof that binds specifically to C5 comprising a heavy chain/light chain amino acid sequence pair of SEQ ID NOs: 353/354.

6. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof that binds specifically to C5 according to claim 1 and a pharmaceutically acceptable carrier or diluent.

7. The antibody or antigen-binding fragment thereof of claim 1 which is an antibody.

8. The antibody or antigen-binding fragment thereof of claim 2 which is an antibody.

9. The antibody or antigen-binding fragment thereof of claim 5 which is an antibody.

10. A pharmaceutical composition comprising the antibody of claim 7 and a pharmaceutically acceptable carrier or diluent.

11. A pharmaceutical composition comprising the antibody of claim 8 and a pharmaceutically acceptable carrier or diluent.

12. A pharmaceutical composition comprising the antibody of claim 9 and a pharmaceutically acceptable carrier or diluent.

13. A reusable pen delivery device comprising the pharmaceutical composition of claim 10 .

14. A reusable pen delivery device comprising the pharmaceutical composition of claim 11 .

15. A reusable pen delivery device comprising the pharmaceutical composition of claim 12 .

16. An autoinjector delivery device comprising the pharmaceutical composition of claim 10 .

17. An autoinjector delivery device comprising the pharmaceutical composition of claim 11 .

18. An autoinjector delivery device comprising the pharmaceutical composition of claim 12 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2017
From: HU, YING; LATUSZEK, ADRIANNA; ROMANO, CARMELO; OLSON, WILLIAM
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 044313/0069 →
Continuity (4)
Provisional Application 62349705 · Jun 14, 2016
Provisional Application 62405561 · Oct 7, 2016
Provisional Application 62422107 · Nov 15, 2016
Related Publication 20170355757A1 · Dec 14, 2017
Cited By (2)
US 12,459,992 US 12,655,201